abil
cyclodextrin
enhanc
antivir
activ
phosphodiest
oligodeoxynucleotid
investig
oligodeoxynucleotid
complementari
initi
region
mrna
code
spike
protein
contain
intergen
consensu
sequenc
enter
coronaviru
test
antivir
action
viru
growth
human
adenocarcinoma
cell
phosphodiest
oligodeoxynucleotid
show
limit
effect
viru
growth
rate
viral
inhibit
cell
treat
mm
oligodeoxynucleotid
respect
multipl
infect
infecti
particl
per
cell
condit
phosphorothio
analogu
exhibit
stronger
antivir
activ
inhibit
increas
inhibitori
effect
analogu
antisens
northern
blot
analysi
show
sequencedepend
mechan
action
appear
inhibit
mrna
transcript
conclud
coronaviru
intergen
consensu
sequenc
good
target
antisens
oligonucleotid
antivir
action
properti
phosphodiest
oligonucleotid
improv
complex
cyclodextrin
import
increas
antivir
activ
inhibit
obtain
mm
oligonucleotid
complex
cyclodextrin
deriv
molar
ratio
studi
suggest
use
cyclodextrin
deriv
carrier
phosphodiest
oligonucleotid
deliveri
may
effect
method
increas
therapeut
potenti
compound
viral
infect
use
antisens
oligonucleotid
interest
approach
studi
cellular
viral
gene
function
block
gene
express
oligonucleotid
consid
ideal
agent
inhibit
viral
replic
due
part
high
viral
dna
rna
sequenc
agent
success
employ
block
replic
cellular
express
sever
virus
includ
herp
simplex
viru
cytomegaloviru
especi
human
viru
howev
vulner
oligonuleotid
nucleas
attack
combin
intracellular
distribut
uptak
properti
limit
therapeut
potenti
avoid
problem
nucleas
digest
improv
cellular
uptak
oligonucleotid
either
chemic
internucleosid
phosphodiest
linkag
ribos
sugar
variou
oligonucleotid
conjug
test
one
chemic
analog
wide
employ
enhanc
stabil
phosphorothio
oligonucleotid
although
analog
increas
resist
degrad
vivo
vitro
exhibit
non
activ
oligonucleotid
conjug
includ
oligonucleotid
adsorb
onto
poli
isobutylcyanoacryl
nanoparticl
encapsul
liposom
conjug
cholesterol
strategi
result
increas
cellular
uptak
oligonucleotid
stabil
nucleas
howev
inher
properti
cholesterol
liposom
nanoparticl
carrier
led
increas
immunogen
oligonucleotid
complex
tendenc
complex
phagocytos
reticuloendotheli
system
investig
cyclodextrin
chemistri
increas
sinc
sever
decad
cyclodextrin
molecular
host
act
carrier
framework
describ
group
cyclic
polysaccharid
contain
glucos
unit
linkag
acd
bcd
gcd
respect
glucos
unit
possess
hydrophob
intern
caviti
includ
variou
small
molecul
peripher
structur
contain
larg
number
hydroxyl
group
make
molecul
water
solubl
cyclodextrin
form
complex
numer
compound
bcyclodextrin
employ
numer
applic
wide
varieti
cyclodextrin
deriv
studi
enhanc
solubl
avail
variou
watersolubl
waterinsolubl
pharmacolog
agent
approach
use
cyclodextrin
deriv
recent
studi
increas
cellular
uptak
phosphorothio
oligonucleotid
work
investig
abil
nativ
band
gcyclodextrin
bcyclodextrin
deriv
carrier
enhanc
antivir
activ
phosphodiest
oligonucleotid
direct
toward
initi
region
mrna
code
spike
protein
contain
intergen
consensu
sequenc
enter
coronaviru
nativ
cyclodextrin
purchas
roquettefr
dijon
franc
bcyclodextrin
bcd
wackerchemi
gmbh
lyon
franc
gcyclodextrin
gcd
chemic
cyclodextrin
synthetis
laboratori
accord
sgalbcd
heptaki
sgal
bcd
heptaki
ethylamino
cyclomaltoheptaos
ethanediamino
bcd
deriv
solubl
distil
water
steril
mm
membran
millipor
franc
use
chemic
structur
present
fig
oligonucleotid
purchas
appligen
strasbourg
franc
antisens
sequenc
h
tggtattagatttgtaca
h
synthet
natur
phosphodiest
oligo
phosphorothio
analog
oligo
sens
sequenc
h
accataatctaaacatgt
h
synthet
phosphorothio
analog
oligo
random
sequenc
h
gaattgtgatatttcatg
h
synthet
phosphorothio
analog
r
oligo
test
oligonucleotid
hplc
lyophil
powder
dissolv
distil
water
strain
bovin
enter
coronaviru
becv
obtain
laport
inra
jouyenjosa
franc
propag
human
rectal
adenocarcinoma
tumor
cell
line
grown
rpmi
medium
icn
biomed
inc
costa
mesa
ca
usa
supplement
foetal
calf
serum
fc
life
technolog
eragni
franc
mg
ml
antibiot
roussel
uclaf
romainvil
franc
incub
c
day
atmospher
contain
co
complex
prepar
take
account
band
cyclodextrin
solubl
data
accord
higuchi
connor
cyclodextrin
regular
cyclic
oligosaccharidyl
molecul
exhibit
troncon
ring
simplic
repres
truncat
cone
wider
side
form
secondari
group
narrow
side
primari
volum
mm
phosphodiest
oligonucleotid
oligo
ad
mm
bcd
mm
gcd
mm
sgalbcd
mm
sgal
bcd
mm
ethanediamino
bcd
ml
total
volum
rpmi
medium
solut
mix
overnight
c
vortex
rpm
rotatest
apparatu
illkirch
franc
result
complex
immedi
test
complex
format
control
circular
measur
observ
oligonucleotid
absorb
intens
nm
data
shown
cellular
viabil
evalu
mtt
assay
previous
describ
cell
grown
bottom
cultur
plate
costar
cambridg
usa
cell
per
well
treat
vari
concentr
oligonucleotid
mm
nativ
cyclodextrin
mm
cd
deriv
mm
h
c
end
incub
period
cytotox
effect
drug
evalu
determin
mitochondri
dehydrogenas
activ
use
mtt
bromid
sigma
chemic
co
st
loui
mo
usa
absorb
solubil
materi
determin
use
titertek
multiscan
mk
ii
apparatu
labsystem
helsinki
finland
cytotox
effect
correspond
decreas
purpl
formazan
product
result
shown
averag
three
experi
cell
expos
h
c
variou
concentr
free
oligonucleotid
oligonucleotid
complex
cyclodextrin
time
inocul
becv
suspens
multipl
infect
moi
pfu
cell
plaqu
form
unit
cell
h
postinfect
viru
titrat
perform
plaqu
form
assay
use
crystal
violet
visual
previous
describ
interpret
viral
titer
interv
determin
taken
consider
intracellular
rna
extract
infect
cell
acid
guanidinium
thiocyanatephenolchloroform
method
use
commerci
messag
system
kit
bioprob
system
montreuilsousboi
franc
rna
pellet
dissolv
nucleas
free
water
adjust
formaldehyd
formamid
mop
morpholinepropan
sulfon
acid
buffer
mm
mop
ph
mm
sodium
acet
mm
edta
sampl
denatur
c
min
analyz
electrophoresi
agaros
gel
formaldehyd
mop
buffer
previous
describ
electrophoresi
gel
treat
mm
naoh
min
soak
depc
diethylpyrocarbon
treat
water
sspe
sspe
nacl
sodium
phosphat
ph
edta
min
rna
transfer
overnight
hybondn
nylon
membran
amersham
buckinghamshir
england
sspe
bake
c
h
nylon
membran
prehybrid
h
c
plastic
bag
contain
solut
formamid
denhardt
solut
ficol
polyvinylpyrrolidin
bovin
serum
albumin
sd
sspe
mgml
sonic
calf
thymu
dna
hybrid
done
overnight
solut
c
use
p
dna
probe
prepar
randomprim
label
gel
becv
h
end
cdna
fragment
kb
previous
describ
membran
wash
twice
room
temperatur
min
sspe
sd
c
min
sspe
sd
c
min
sspe
sd
membran
airdri
autoradiograph
xray
kodak
x
omat
ny
usa
oligonucleotid
cell
viabil
effect
evalu
mtt
assay
h
treatment
cell
increas
concentr
mm
oligonucleotid
figur
show
r
oligonucleotid
exhibit
inhibitori
effect
viabil
cell
concentr
test
antivir
activ
antisens
phosphodiest
oligo
phosphorothio
analog
oligo
evalu
describ
materi
method
cell
expos
variou
oligonucleotid
concentr
mm
mm
time
infect
becv
suspens
moi
pfucel
h
c
h
postinfect
viru
titer
treat
infect
cell
determin
compar
obtain
control
infect
cell
observ
oligonucleotid
cell
viabil
cell
grown
cellswel
treat
h
r
oligonucleotid
concentr
rang
mm
cell
viabil
evalu
dehydrogenas
activ
mtt
assay
point
mean
three
independ
experi
perform
triplic
error
bar
repres
standard
error
mean
fig
viral
product
cell
treat
mm
oligo
contrast
oligo
reduc
abil
becv
form
plaqu
cell
cell
treat
mm
oligo
viral
growth
observ
compar
control
infect
cell
result
inhibit
dosedepend
phosphorothio
analogu
exhibit
pronounc
antivir
activ
phosphodiest
oligodeoxynucleotid
viral
multipl
infect
antivir
activ
mm
oligo
presenc
variou
viral
moi
pfucel
also
evalu
result
present
fig
respect
viru
product
observ
cultur
infect
pfucel
contrast
presenc
moi
pfu
cell
use
mm
oligo
inhibit
weakli
viru
infect
obtain
viral
growth
sequenc
effect
phosphorothio
oligonucleotid
viral
growth
order
studi
antivir
activ
phosphorothio
analogu
sens
oligo
antisens
oligo
random
r
oligo
oligonucleotid
compar
test
use
oligonucleotid
concentr
mm
moi
pfucel
show
fig
presenc
r
oligo
oligo
antivir
effect
observ
wherea
mm
oligo
allow
viral
product
result
antisens
sequenc
oligo
antivir
activ
moi
pfucel
mockinfect
medium
contain
fc
expos
mm
either
oligo
r
oligo
oligo
oligonucleotid
viral
suspens
ad
togeth
time
infect
h
postinfect
intracellular
rna
extract
separ
electrophoresi
transfer
membran
hybrid
cdna
probe
repres
h
end
becv
genom
includ
almost
n
part
gene
autoradiogram
fig
show
infect
cell
rna
speci
could
detect
h
postinfect
mrna
transcrib
nonequimolar
amount
name
mrna
accord
decreas
order
size
code
viral
protein
n
respect
alreadi
describ
although
oligonucleotid
sequenc
complementari
synthesi
mrna
reduc
cell
treat
oligo
condit
mrna
product
affect
cell
treat
sens
oligo
oligo
random
oligo
r
oligo
compar
untreat
infect
cell
cyclodextrin
cell
viabil
effect
nativ
cd
cyclodextrin
deriv
cell
viabil
test
nativ
bcd
gcd
fig
inhibit
cellular
viabil
concentr
vari
mm
contrari
bcd
stimul
cell
dehydrogenas
activ
obtain
increas
cell
viabil
concentr
rang
mm
concern
cd
deriv
observ
fig
sgalbcd
sgal
bcd
exhibit
fig
northern
blot
analysi
subgenom
rna
intracellular
rna
extract
h
postinfect
separ
agaros
gel
electrophoresi
transfer
nylon
membran
probe
prepar
random
prime
p
label
enter
cdna
fragment
correspond
h
end
genom
rna
autoradiogram
expos
overnight
c
intensifi
screen
infect
cell
moi
pfucel
infect
cell
treat
r
oligo
oligo
oligo
oligonucleotid
use
concentr
mm
tabl
oligo
viral
product
similar
previous
obtain
complex
cyclodextrin
inhibit
improv
viral
product
obtain
oligo
molar
ratio
oligonucleotid
sgalbcd
improv
antivir
activ
evalu
molar
ratio
oligo
sgalbcd
antivir
activ
phosphodiest
oligonucleotid
oligo
use
concentr
mm
sgalbcd
concentr
rang
mm
mm
show
fig
molar
ratio
effect
sgalbcd
viral
multipl
evalu
result
tabl
show
inhibitori
effect
viral
product
cell
inocul
viral
suspens
moi
pfucel
presenc
sgalbcyclodextrin
variou
concentr
h
postinfect
viru
titer
determin
plaqu
form
assay
l
lower
limit
interv
l
u
upper
limit
interv
bcyclodextrin
deriv
observ
nevertheless
mm
stimul
viral
growth
coronavirus
origin
replic
procedur
candid
antisens
strategi
virus
caus
acut
persist
infect
might
etiolog
agent
autoimmun
diseas
envelop
virus
contain
singlestrand
positivesens
polyadenyl
genom
possess
three
four
major
structur
protein
coronavirus
spike
membran
nucleocapsid
n
protein
haemagglutininesteras
protein
addit
least
four
gene
encod
nonstructur
protein
replic
infect
cell
genom
rna
transcrib
genomes
negativestrand
rna
serv
templat
synthesi
hcotermin
nest
set
subgenom
mrna
hproxim
region
present
next
smaller
rna
set
use
translat
anoth
uniqu
featur
coronaviru
mrna
h
end
genom
rna
mrna
contain
nucleotidelong
leader
sequenc
studi
made
murin
coronaviru
mous
hepat
shown
h
end
leader
sequenc
contain
repeat
ucuaa
pentanucleotid
sequenc
includ
uniqu
ucuaaac
consensu
sequenc
similar
sequenc
observ
intergen
region
genom
rna
thu
mrna
transcript
start
result
interact
leader
sequenc
positivestrand
rna
complementari
antilead
sequenc
negativestrand
rna
intergen
consensu
sequenc
common
transcript
initi
site
mrna
could
interest
target
antisens
oligonucleotid
target
antisens
oligodeoxynucleotid
complementari
initi
region
mrna
code
protein
contain
uniqu
ucuaaac
intergen
consensu
sequenc
promot
genom
rna
subgenom
mrna
transcript
shown
mm
phosphorothio
antisens
oligo
oligonucleotid
abl
inhibit
enter
coronaviru
growth
cell
moi
intens
inhibitori
effect
oligo
function
concentr
multipl
viral
infect
previou
studi
inhibit
gene
express
antisens
sequenc
cell
requir
oligonucleotid
concentr
rang
mm
report
great
varieti
biolog
model
investig
render
comparison
experiment
condit
viral
product
inhibit
phosphodiest
antisens
oligo
oligonucleotid
absenc
inhibitori
effect
oligonucleotid
may
relat
rapid
degrad
nucleas
reduc
cellular
uptak
observ
cellular
uptak
oligonucleotid
reveal
data
shown
mm
oligo
quickli
h
intern
cell
present
cytoplasm
nucleu
cell
contrast
intracellular
local
even
mm
oligo
notic
studi
shown
uptak
oligonucleotid
complex
process
depend
mani
factor
includ
cell
type
structur
chemic
oligonucleotid
temperatur
time
incub
uptak
satur
process
probabl
occur
kd
protein
true
role
protein
still
unknown
stronger
inhibitori
effect
observ
oligo
could
relat
increas
stabil
lipophil
result
replac
oxygen
atom
sulfur
thu
report
phosphorothio
oligonucleotid
strongli
associ
cell
membran
correspond
phosphodiest
previous
observ
antivir
activ
oligo
due
oligonucleotid
induc
cytotox
assay
measur
hostcel
viabil
reveal
oligonucleotid
test
affect
level
cellular
metabol
even
high
concentr
mm
excess
inhibitori
concentr
mm
noteworthi
oligonucleotid
inhibit
hiv
replic
especi
high
concentr
random
unrel
phosphorothio
oligonucleotid
r
oligo
base
composit
oligo
without
homolog
known
sequenc
genom
rna
show
activ
therefor
inhibit
viru
growth
seem
due
effect
addit
sens
oligonucleotid
oligo
concentr
employ
inhibit
viru
growth
show
antivir
mechan
action
oligo
antisens
result
northern
blot
analysi
transcript
reduc
infect
cell
mm
oligo
use
contrast
rna
level
unaffect
control
r
oligo
sens
oligo
phosphorothio
oligonucleotid
addit
northern
blot
show
antisens
phosphorothio
oligo
act
transcript
inhibit
mechan
duplex
made
hybrid
positivestrand
genom
rna
oligo
stop
synthesi
full
length
neg
strandedrna
prevent
subgenom
genom
rna
synthesi
noninhibitori
effect
sens
oligonucleotid
could
explain
consid
viral
replic
mechan
transcript
mrna
initi
hybrid
leader
antilead
sequenc
antilead
sequenc
contain
anticonsensu
sequenc
target
sens
oligonucleotid
consequ
assum
competit
occur
leader
sequenc
sens
oligonucleotid
hybrid
target
competit
might
favour
leader
sequenc
mainli
due
total
complementar
target
due
also
highest
result
provid
evid
coronaviru
intergen
consensu
sequenc
positivestrand
genom
rna
good
target
antisens
oligonucleotid
antivir
action
inhibit
effect
viru
growth
mediat
abil
oligonucleotid
interfer
mrna
transcript
howev
potenti
disadvantag
may
inher
use
phosphorothio
analog
assur
substitut
phosphorothio
phosphodiest
oligonucleotid
would
preserv
abil
bind
similar
high
target
addit
studi
shown
sulfur
phosphorothio
may
provid
novel
reactiv
center
dna
molecul
drug
interact
interact
may
affect
antisens
compound
may
also
act
viral
polymeras
inhibit
interfer
viral
adsorpt
penetr
inhibit
cellular
enzym
growth
factor
moreov
commerci
phosphorothio
tend
expens
phosphodiest
oligonucleotid
avoid
problem
attempt
improv
properti
phosphodiest
oligonucleotid
complex
cyclodextrin
supermolecul
compar
biolog
activ
phosphodiest
antisens
oligonucleotid
oligo
either
free
complex
nativ
bcd
cd
bcyclodextrin
deriv
oligo
complex
either
nativ
b
gcd
ethanediamino
bcd
deriv
decreas
viral
multipl
observ
inhibit
higher
complex
sgalbcd
sgal
bcd
moreov
antivir
activ
oligo
complex
sgalbcd
improv
complex
perform
oligocd
molar
ratio
mm
mm
level
inhibit
obtain
presenc
mm
oligo
concentr
three
fold
use
complex
demonstr
last
year
substitut
cyclodextrin
longer
biolog
amorph
compound
could
exhibit
biolog
activ
antivir
activ
check
chemic
bcd
induc
cyclodextrin
antivir
anticellular
effect
sgalbcd
induc
inhibitori
effect
viral
multipl
concentr
use
prepar
complex
moreov
assay
measur
cell
viabil
show
cytotox
action
cyclodextrin
observ
exclud
possibl
antivir
activ
obtain
oligosgalbcd
complex
due
effect
sgalbcd
result
might
conclud
complex
oligonucleotid
cyclodextrin
protect
oligo
degrad
nucleas
perhap
protect
phosphodiest
group
cellular
uptak
studi
recent
report
intens
fitc
conjug
phosphorothio
oligonucleotid
greatli
increas
oligonucleotid
complex
cyclodextrin
deriv
indic
complex
increas
cellular
uptak
case
might
expect
chemic
nativ
bcd
substitut
hydroxyl
primari
alcohol
one
glucos
unit
ring
thiogalactos
residu
improv
cellular
uptak
oligo
ligandcarbohydr
cell
receptor
interact
surfac
numer
normal
malign
eukaryot
cell
cover
lectin
galactosesubstitut
bcd
might
use
drug
carrier
target
oligonucleotid
vivo
anoth
possibl
may
also
contribut
enhanc
antivir
activ
oligo
complex
cyclodextrin
complex
could
modifi
intracellular
distribut
antisens
oligonucleotid
probabl
oligonucleotidecyclodextrin
complex
enter
cell
process
differ
endocytosi
pathway
oligonucleotid
may
trap
within
endosom
lysosom
vesicl
studi
achiev
studi
intracellular
distribut
oligonucleotid
treatment
oligonucleotidecyclodextrin
complex
elucid
mechan
interact
oligodeoxynucleotid
cyclodextrin
